

February 25, 2020

Venturis Therapeutics Inc. Announces Exclusive License Agreement with James Cook University in Queensland, Australia

Dallas, TX – Venturis Therapeutics (“VT” or the “Company”) today announced that it has entered into an exclusive license agreement with James Cook University (“JCU”) for peptide-based intellectual property and technology for use in difficult to treat and chronic wounds. The agreement gives VT exclusive rights to the technology from the laboratory of Prof. Alex Loukas and Prof. Norelle Daly, which will be used in VT’s efforts to develop novel wound healing approaches in a variety of clinical settings.

“We are very pleased to enter into this exciting collaboration with JCU. This demonstrates our corporate commitment to the expansion of our therapeutic pipeline through strategic alliances that provide us access to cutting edge protocols. This collaboration with JCU is key to facilitating breakthrough approaches in wound healing in diabetic and other patient populations.”, VT’s Chairman and CEO, Calvin Wallen, III, stated.

ABOUT VENTURIS THERAPEUTICS

Venturis Therapeutics, Inc. is a biopharmaceutical company developing protein drug candidates to address diseases such as diabetic wounds, severe coronary heart disease, peripheral artery disease, erectile dysfunction, stroke, and spinal disk disease. The active pharmaceutical ingredient (“API”) in our drug candidates is FGF-1, a human protein that stimulates the growth of new blood vessels, thereby increasing the blood supply to ischemic organs and tissues.

FORWARD LOOKING STATEMENTS

This news release contains forward-looking statements that involve risks and uncertainties. Actual results and outcomes may differ materially from those discussed or anticipated. For example, statements regarding expectations for new research, progress with clinical trials or future business initiatives are forward looking statements. Factors that might affect actual outcomes include, but are not limited to, FDA approval of VT drug candidates, market acceptance of VT products by customers, new developments in the industry, future revenues, future expenses, future margins, cash usage, and financial performance. Additionally, until VT is cash flow positive from operations, the Company is dependent upon raising capital to fund its operations and meet its obligations as they come due. There can be no assurance that VT will be able to raise the necessary capital when needed.

SOURCE: Venturis Therapeutics, Inc.
